Published 4 days ago • loading... • Updated 4 days ago

Why Executive MFN Deals Aren't Enough: Q&A with Joe Cunningham

Summary

Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

pharmexec.com

Addressing MFN Innovation Concerns

Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.

4 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated4 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pharmexec.com broke the news 4 days ago on Friday, September 18, 2026.

Sources are mostly out of (0)

Why Executive MFN Deals Aren't Enough: Q&A with Joe Cunningham

1 Articles

1 Articles

Addressing MFN Innovation Concerns

Coverage Details

Bias Distribution

Factuality

Ownership

More stories like this

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs

GLP-1 drugmakers sued over sudden vision loss risk: Reports

Order Defends Timely Opening of Vacancies for New Pharmacists Specialists

Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs

‘Huge step’: Aussie CBD pain pill seeks nod

Similar News Topics

Similar News Topics

More stories like this

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs

GLP-1 drugmakers sued over sudden vision loss risk: Reports

Order Defends Timely Opening of Vacancies for New Pharmacists Specialists

Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs

‘Huge step’: Aussie CBD pain pill seeks nod

Why Executive MFN Deals Aren't Enough: Q&A with Joe Cunningham

1 Articles

1 Articles

Addressing MFN Innovation Concerns

Coverage Details

Bias Distribution Too Big Arrow Icon

Factuality Info Icon

Ownership

More stories like this

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs

GLP-1 drugmakers sued over sudden vision loss risk: Reports

Order Defends Timely Opening of Vacancies for New Pharmacists Specialists

Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs

‘Huge step’: Aussie CBD pain pill seeks nod

Similar News Topics

Similar News Topics

More stories like this

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs

GLP-1 drugmakers sued over sudden vision loss risk: Reports

Order Defends Timely Opening of Vacancies for New Pharmacists Specialists

Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs

‘Huge step’: Aussie CBD pain pill seeks nod

Bias Distribution

Factuality